Skip to main content

Published locations for Anti-TNFs for IBD may double relative risk of demyelinating diseases

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Anti-TNFs for IBD may double relative risk of demyelinating diseases

User login

  • Reset your password
  • /content/anti-tnfs-ibd-may-double-relative-risk-demyelinating-diseases
  • /familypracticenews/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk
  • /gihepnews/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk-demyelinating
  • /internalmedicinenews/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk
  • /internalmedicine/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk
  • /neurology/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk-demyelinating
  • /familymedicine/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk
  • /clinicalneurologynews/article/103306/multiple-sclerosis/anti-tnfs-ibd-may-double-relative-risk